New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2014
07:11 EDTMYGNMyriad Genetics says SGO recommendations support broader genetic test access
Myriad Genetics noted that the Society of Gynecologic Oncology, or SGO, has issued new clinical practice statements surrounding hereditary cancer testing for patients with ovarian and endometrial cancer. The statements are consistent with the recently revised National Comprehensive Cancer Network, or NCCN, guidelines and support broader access to genetic testing for patients with ovarian and endometrial cancer, the company said. Some of the key aspects of the statements include a recommendation that women diagnosed with epithelial ovarian, tubal and peritoneal cancers should be considered for genetic counseling and testing even in the absence of family history and a recommendation that all women diagnosed with endometrial cancer should undergo systematic clinical screening and/or molecular screening for hereditary colon cancer risk.
News For MYGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
07:17 EDTMYGNSociety of Thoracic Surgeons to hold annual meeting
51st Annual Meeting of STS is being held in San Diego, California on January 24-28.
January 23, 2015
15:46 EDTMYGNPiper Jaffray's medtech analysts hold an analyst/industry conference call
Subscribe for More Information
January 20, 2015
07:07 EDTMYGNMyriad RBM joins Institut Pasteur in TB collaboration
Myriad RBM, a wholly owned subsidiary of Myriad Genetics, announced that it will assist the Institut Pasteur in a public-private research collaboration to fight the global tuberculosis, or TB, epidemic. This research project is funded by the Bill & Melinda Gates Foundation through a grant to the Institut Pasteur. The proof-of-concept study will evaluate patients with latent and active TB infections who are affiliated with the South African Tuberculosis Vaccine Initiative clinical study sites. The goals of this study are to field-test Myriad RBM's TruCulture system as a point-of-care blood collection and immune response monitoring method and to stratify patients with active and latent tuberculosis.
January 15, 2015
07:59 EDTMYGNAmerican Society of Clinical Oncology to hold a symposium
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use